Clinical Trial

Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective single-center clinical study, which aims to observe and evaluate the efficacy and safety of apatinib combined with temozolomide and oral etoposide in the treatment of recurrent medulloblastoma in children.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-08-05; most recent amendment 2024-10-09.
Trial Details
NCT Number NCT04501718
Lead Sponsor Beijing Sanbo Brain Hospital
Conditions Recurrent Medulloblastoma
Enrollment 44 participants
Start Date 2020-10-28
Primary Completion 2025-08-31 (estimated)
Study Completion 2025-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-15